Beyond the headline: 11 clinical trial programs shaping medicine in 2026
Clinical trials • October 2026 update
THE EVIDENCE BRIEFING · UPDATED 17 OCTOBER 2026
Clinical trial announcements can change a company’s prospects in minutes. Changing patient care takes longer. A useful reading of the 2026 pipeline asks three questions: what was actually tested, how convincing is the benefit, and what remains to be established?
This Graymedy guide revisits the programs highlighted in BioPharma Dive’s midyear watchlist, adds subsequent sponsor disclosures, and explains the questions behind the headlines. Several anticipated readouts have already arrived. Where only earlier guidance was verified, it is identified as such rather than treated as a current promise.
The principle to keep in view
A positive topline announcement is one step in an evidence chain. The magnitude of benefit, uncertainty, adverse effects and relevance to everyday patients determine how much that step matters.
1. Lung cancer: can a dual-target antibody improve on established treatment?
Program: Summit Therapeutics and Akeso’s ivonescimab · HARMONi-3.
HARMONi-3 compares ivonescimab plus chemotherapy with pembrolizumab plus chemotherapy in first-line metastatic non-small cell lung cancer. Summit’s February update separated squamous and non-squamous cohorts, with different analysis schedules. The company anticipated final progression-free survival analysis for the squamous cohort in the second half of 2026, while the non-squamous cohort’s final analysis was projected for the first half of 2027.
Graymedy’s reading: A trial name can conceal more than one clinical question. Results from one histology should not be generalized to the other. Delaying progression and extending life also require separate interpretation; an immature survival analysis cannot settle a survival claim. Source: Summit’s trial and timeline update.
2. Alzheimer’s-related psychosis: a new indication needs its own proof
Program: Bristol Myers Squibb’s Cobenfy · ADEPT.
BMS described ADEPT-2 as a randomized, double-blind, placebo-controlled Phase 3 study of Cobenfy in psychosis associated with Alzheimer’s disease dementia. Its December 2025 continuation announcement projected ADEPT-2, ADEPT-1 and ADEPT-4 results by the end of 2026. That is the dated guidance verified for this briefing; it does not establish that a readout has occurred.
Graymedy’s reading: Evidence in schizophrenia cannot answer whether a medicine offers an acceptable balance of benefit and harm in dementia. Readers should look for the size and durability of psychosis improvement, treatment discontinuations, adverse events and the handling of study-site irregularities. The analysis population matters as much as the headline statistical result. Source: BMS ADEPT-2 update.
3. Chronic hives: pivotal results have moved the story forward
Program: Celldex’s barzolvolimab · EMBARQ-CSU1 and EMBARQ-CSU2.
On September 22, Celldex reported that both Phase 3 trials met their primary and all key secondary endpoints across both dose groups. The studies enrolled patients whose chronic spontaneous urticaria was inadequately controlled by H1 antihistamines. The primary measure was change in weekly urticaria activity score at week 12. Celldex reported a favorable safety profile through 24 weeks, with treatment continuing to 52 weeks and a US filing planned for 2027.
Graymedy’s reading: These are now reported pivotal findings, rather than an upcoming catalyst. The next useful questions concern sustained symptom control, results in previously treated patients and longer follow-up. A sponsor’s assessment of tolerability should be read alongside detailed adverse-event and discontinuation tables. Source: Celldex’s September results.
4. Personalized cancer therapy: a milestone in melanoma
Program: Moderna and Merck’s intismeran autogene plus Keytruda · INTerpath-001.
On August 19, the companies announced that their Phase 3 study met the recurrence-free survival and distant metastasis-free survival endpoints in patients with completely resected stage IIB–IV melanoma. The individualized mRNA therapy is designed around mutations in each patient’s tumor. The announced comparison was the combination against Keytruda alone in the postoperative setting. The companies said they would present data and engage regulators on submissions.
Graymedy’s reading: The reported result is an important development for this specific treatment setting. It does not establish efficacy in every cancer, nor does it make recurrence-free survival interchangeable with overall survival. Detailed effect sizes, follow-up and the practical demands of producing an individualized therapy will shape its clinical meaning. Source: Merck and Moderna announcement.
5. Cardiac amyloidosis: the overall result must lead the interpretation
Program: Ionis and AstraZeneca’s eplontersen · CARDIO-TTRansform.
Ionis announced on July 9 that CARDIO-TTRansform did not meet its primary endpoint: the combined outcome of cardiovascular mortality and recurrent cardiovascular clinical events through week 140. Adding eplontersen to contemporary standard care did not produce a statistically significant benefit in the overall population. Many participants received a stabilizer. The sponsor also reported a nominally significant finding in a prespecified monotherapy subgroup.
Graymedy’s reading: A subgroup signal does not reverse a missed primary endpoint. It can generate a more focused question, but its interpretation depends on the statistical plan, consistency and supporting evidence. For clinicians, the central issue is the incremental value of a new treatment on top of the care patients already receive. Source: Ionis’s primary-endpoint update.
6. Lupus: keep systemic and skin-disease evidence separate
Program: Biogen’s litifilimab · TOPAZ-1 and TOPAZ-2.
Biogen’s 2026 pipeline materials identified the two Phase 3 systemic lupus erythematosus studies as anticipated readouts by year-end. Separately, its October 2 announcement described 52-week Phase 2 findings in cutaneous lupus from AMETHYST, with Phase 3 AMETHYST results expected in the first half of 2027. These are different studies and different evidence packages.
Graymedy’s reading: Skin improvement in cutaneous lupus cannot substitute for the prespecified outcomes in systemic lupus. For TOPAZ, readers should look for reproducibility across both trials, background treatment, rescue medication and whether symptom improvements are meaningful and durable. Two trials offer an opportunity to assess consistency rather than relying on a single favorable result. Source: Biogen’s 2026 readout guidance; October AMETHYST update.
7. Pneumococcal vaccines: broader coverage comes with statistical detail
Program: Vaxcyte’s VAX-31 · OPUS-1.
Vaxcyte reported on October 5 that OPUS-1 met its prespecified primary endpoints. In adults aged 50 and older, all 28 serotypes shared with the comparator vaccines met the trial’s primary noninferiority criteria. However, in individual comparisons against Capvaxive, 17 of 19 shared serotypes met the stricter threshold; two met the historical, less stringent threshold. The company reported similar safety profiles and projected OPUS-2 and OPUS-3 results in the first half of 2027.
Graymedy’s reading: The overall primary analysis and individual comparator analyses answer different questions. Both belong in an accurate account. Immune-response results support vaccine development, but should not be presented as a directly measured percentage reduction in pneumonia cases. Source: Vaxcyte’s OPUS-1 release.
8. Oral immune therapy: success in skin disease leaves a bowel-disease question
Program: Takeda’s zasocitinib · Phase 2 inflammatory bowel disease studies.
Takeda’s September 14 update said the FDA accepted zasocitinib’s application for plaque psoriasis under Priority Review, with a target decision in the first quarter of 2027. The same announcement identified ongoing Phase 2 evaluation in Crohn’s disease and ulcerative colitis. Those bowel-disease studies remain a distinct development question; the psoriasis filing is not evidence of efficacy or approval in inflammatory bowel disease.
Graymedy’s reading: Convenience matters for chronic treatment, but an oral route alone does not establish a better therapy. Bowel-disease evidence must address disease-specific clinical and inflammatory outcomes, the studied doses and adverse effects. A strong result in one inflammatory condition supplies a rationale to investigate another, rather than an answer. Source: Takeda’s regulatory and development update.
9. Muscle-directed RNA: biological promise faces a functional test
Program: Novartis’s del-desiran · HARBOR in myotonic dystrophy type 1.
On September 8, Novartis announced that HARBOR did not achieve statistically significant improvement against placebo on its primary endpoint, video hand opening time. The sponsor reported signs of clinical activity in secondary and exploratory analyses and said it would review the full dataset and discuss the development path with health authorities.
Graymedy’s reading: This is a reminder that delivering a therapy to a difficult tissue and improving a prespecified functional outcome are separate hurdles. Secondary findings may help explain the result, but should be labeled clearly and assessed in the context of the failed primary test. For patients, the relevant question is whether treatment produces a reliable change in daily function. Source: Novartis’s HARBOR update.
10. Stroke prevention: efficacy and bleeding belong together
Program: BMS and Johnson & Johnson’s milvexian · LIBREXIA.
BMS’s November 2025 update said LIBREXIA-AF and LIBREXIA-STROKE would continue after the ACS study stopped, with results expected in 2026. That dated statement does not itself establish the outcome of either continuing study. In stroke prevention, efficacy and bleeding must be interpreted together. Source: BMS LIBREXIA update.
11. Obesity: substantial weight loss needs a complete clinical picture
Program: Lilly’s retatrutide · TRIUMPH.
Retatrutide has already produced reported Phase 3 results. Lilly reported average weight loss of 28.3% at 80 weeks with the 12 mg dose in TRIUMPH-1, under its efficacy estimate. Its July update also reported positive TRIUMPH-2 and TRIUMPH-3 findings. The populations differed, including people with type 2 diabetes and those with established cardiovascular disease. Source: TRIUMPH-1 announcement; TRIUMPH-2 and TRIUMPH-3 update.
Graymedy’s reading: Weight loss estimates depend on the population and analytical approach. Cross-trial percentages do not establish head-to-head superiority. Cardiovascular benefit also requires cardiovascular outcome evidence; it cannot be inferred simply from weight loss in participants who have heart disease.
A reader’s checklist for the next announcement
- Start with the primary endpoint. Identify the question the trial was designed to answer before reading subgroup claims.
- Find the comparator and population. An improvement over placebo and an improvement over current treatment carry different implications.
- Read the size of the effect. Statistical significance alone does not describe the practical benefit.
- Check follow-up and missing data. Durability, withdrawals and treatment discontinuations can change the interpretation.
- Read safety with efficacy. Common side effects and uncommon serious events both matter.
- Separate the milestones. Topline results, full publication, regulatory review and availability are different steps.
The most useful question is what the evidence changes for the people who might receive treatment—and what evidence is still missing.
Sources, attribution and editorial note
Originating reporting: This independently written Graymedy analysis was prompted by BioPharma Dive’s “10 clinical trials to watch in the second half of 2026”, published June 29, 2026, by BioPharma Dive staff. Credit to its reporting team for identifying the watchlist. Subsequent developments and trial context are attributed to the linked sponsor disclosures throughout this article.
Scope: Editorial review dated October 17, 2026. This is a selected evidence briefing, not a complete live trial-status registry. Dated company guidance is identified where no newer outcome was verified. Sponsor announcements describe company-reported findings; full datasets and regulatory assessments may add context.
Photo: Rhoda Baer / NIAMS.
Medicines
View more
A limited course of treatment is becoming a practical possibility for some people with chronic hepatitis B. The FDA’s October 20 approval of Hibsago (bepirovirsen) adds an antisense medicine to existing antiviral therapy for carefully selected adults. The advance is meaningful, but it does not mean every patient can stop long-term treatment. In two trials, 24% of Hibsago recipients met the criteria to discontinue their existing antiviral, compared with none receiving placebo. At 24 weeks after stopping all hepatitis B treatment, 19% of Hibsago recipients retained viral control with undetectable hepatitis B surface antigen. Selection comes before treatment The US indication covers adults without cirrhosis who have received nucleos(t)ide analogue therapy for at least six months, have suppressed HBV DNA, and have surface antigen levels no higher than 3,000 IU/mL on an FDA-authorized test. Bepirovirsen targets viral RNA, reducing production of viral proteins as well as supporting suppression of the virus. Hibsago is given for up to 24 weeks alongside the existing antiviral. That background therapy continues for at least another 24 weeks. Any later withdrawal depends on the clinician’s assessment and laboratory criteria; it is not an automatic next step. The follow-up is part of the medicine The prescribing information carries boxed warnings for liver flares and potentially life-threatening reductions in platelets. Kidney function and inflammatory reactions also require attention. Laboratory testing before, during and after treatment is central to safe use. HBV can worsen after antiviral discontinuation, so continued follow-up matters even when treatment has ended. For pharma, the broader signal is a move toward finite regimens tied to biomarkers and a defined monitoring pathway. For patients, the immediate question is narrower: whether their disease profile and access to follow-up make this option appropriate. FDA approval · Prescribing information Image: CDC / Betty Partin, PHIL.
Ultomiris reaches IgA nephropathy—with a kidney-outcome question still open
For shorter TB treatment, a drug must reach the bacteria’s hiding place
A new head-and-neck cancer approval brings an option—and an evidence question
A new cancer-drug indication can change the timing of a treatment discussion. It can also make a laboratory result more consequential. The latest U.S. approval for talazoparib brings those changes together for a genetically defined group of people with metastatic prostate cancer. On 26 October, the FDA approved talazoparib, sold as Talzenna, with enzalutamide for adults whose metastatic prostate cancer is androgen pathway modulation-naïve or sensitive and has a qualifying homologous recombination repair gene mutation. An FDA-authorized test must establish that molecular eligibility. The decision is specific, rather than a recommendation for everyone with prostate cancer. The genetic result is part of the treatment Homologous recombination repair, usually shortened to HRR, helps cells repair DNA damage. Alterations in this pathway provide the rationale for studying a PARP inhibitor such as talazoparib. Enzalutamide acts through androgen-receptor signalling. The combination brings two different biological approaches into the same regimen. For patients, the practical starting point is a precise explanation of their result: which alteration was found, which test detected it and whether it matches the approved indication. A headline about a targeted treatment does not establish eligibility. Nor can a tissue photograph reveal the molecular information required for selection. What Neeraj Agarwal and colleagues tested TALAPRO-3, reported by Neeraj Agarwal and colleagues in the New England Journal of Medicine, randomly assigned 599 patients to talazoparib plus enzalutamide or placebo plus enzalutamide. Participants also received androgen-deprivation therapy. It was a double-blind phase 3 trial funded by Pfizer. At three years, the estimated proportion alive without imaging-based progression was 77% with talazoparib and 56% with placebo. That 21-percentage-point difference gives an absolute view of the finding. The reported hazard ratio for progression or death was 0.48. The endpoint combines progression detected on imaging with death. It is not a measure of the proportion cured, and a hazard ratio is not a personal forecast. The result supports a treatment option in the population studied, with benefits that still have to be weighed against harms. A survival claim would go beyond the evidence The FDA says overall-survival data were immature when the progression analysis was performed. Delaying progression is meaningful, but it should not be presented as a proven extension of life in this earlier treatment setting. Further follow-up addresses a different and important question. This distinction also helps readers interpret promotional language. Pfizer's earlier trial announcement emphasised the relative reduction in progression or death. That description refers to the trial endpoint and comparison; it does not mean the medicine halves every participant's chance of dying. The monitoring burden belongs beside the benefit The trial report found serious adverse events in 42% of the talazoparib group and 32% of the control group. Severe anaemia was a prominent problem. The current prescribing information describes substantial rates of dose interruption and reduction in TALAPRO-3, showing that an oral regimen can still require intensive management. The label warns about myelosuppression and myelodysplastic syndrome or acute myeloid leukaemia, among other risks. Blood-count monitoring and clinical review are therefore central to treatment. The dosing information also includes adjustments for particular circumstances; patients should not change doses themselves. These are reasons for an individual discussion about fitness, other medicines, existing blood problems and the support needed during therapy. Convenience matters, but taking a medicine at home does not remove the need for a specialist team or a plan for reporting symptoms. Keeping a written record of the testing result and the proposed monitoring schedule may help patients follow that discussion and share it with the professionals involved in their care. Questions for the next appointment Graymedy's reading is that the most useful consequence of this approval is a more specific consultation. A patient can ask whether molecular testing is complete, why this combination is being considered now, what alternative regimens are relevant and which outcomes the team hopes to improve. It is also reasonable to ask how often blood tests and visits will be needed, what would trigger a treatment pause and how costs or access are handled locally. The FDA decision concerns the United States. The agency's announcement said collaborating Australian and Canadian reviews were ongoing at that point; it did not establish worldwide availability. Agarwal and colleagues' work strengthens the evidence for earlier, genetically selected treatment. Its value is clearest when the test result, progression benefit, remaining survival uncertainty and monitoring requirements are discussed together. That is a more useful update than treating approval as the end of the clinical conversation. Sources: FDA approval, 26 October 2026; TALAPRO-3 trial report; Current Talzenna prescribing information; Pfizer's May trial announcement. Photo: Nephron / Wikimedia Commons, CC BY-SA 3.0; resized. Reviewed 5 November 2026. Independently written from public sources; no interview was conducted. General information, not individual medical advice.
Sixteen bacterial strains, one clinical question: can SER-155 prevent bloodstream infections?
Allopurinol for gout: treating the urate level between attacks
Voceryq gains FDA approval to reduce repeat surgery for a rare airway disease
A growing treatment puzzle People living with several long-term conditions may receive medicines from different specialists, urgent-care services and primary-care teams. Each prescription may have been reasonable when introduced, yet the combined regimen can become difficult to manage. Interactions, overlapping treatments, changing kidney function and complex schedules can alter the balance between benefit and harm. A structured medication review looks at the whole person, rather than judging each medicine in isolation. What polypharmacy means Polypharmacy commonly describes the use of multiple medicines, but the number alone does not establish a problem. Several treatments may be essential for someone with complex disease. The more useful question is whether every medicine still has an appropriate indication and whether the overall plan matches current health needs. Reviews should consider prescribed tablets, over-the-counter remedies, vitamins and herbal products because patients may not think to mention everything they take. How a review begins Clinicians first need an accurate list: medicine name, dose, timing, purpose and actual use. The patient's account is crucial. Someone may skip an afternoon dose because of work, halve a tablet after dizziness or continue a medicine that was supposed to stop. A nonjudgmental conversation can reveal such differences. Pharmacy dispensing records, hospital summaries and medicine containers can help, but none replaces asking what happens in daily life. Benefits, burdens and changing priorities A medicine that prevents a future complication may be worthwhile for many years, while another offers little benefit once circumstances change. Some treatments require monitoring, have cumulative adverse effects or are difficult to swallow. Older adults may be especially vulnerable to certain sedating and anticholinergic medicines, although risk depends on the individual and the product. Decisions must account for goals such as symptom relief, independence and avoiding hospital visits, not merely laboratory targets. Deprescribing is a clinical process Deprescribing means supervised reduction or withdrawal when potential harms exceed expected benefits. It does not mean abruptly stopping treatment or assuming fewer medicines are always safer. Some medicines require gradual tapering and monitoring because sudden withdrawal can cause rebound symptoms or serious complications. A clinician may change one treatment at a time, agree on what to monitor and schedule reassessment. Patients should not stop prescribed medicines solely because they read about polypharmacy. Communication across specialties Medication decisions can be complicated when one specialist adds a drug without knowing what another has prescribed. Shared records are helpful but may not capture every pharmacy or over-the-counter purchase. A designated clinician or pharmacist can coordinate the list and communicate changes across teams. When a medicine is stopped, documenting why helps prevent it from being restarted inadvertently during the next hospitalization. Clear explanations also reduce confusion when packaging or brand names change. The patient perspective Side effects do not always appear on a laboratory report. Fatigue, falls, dry mouth, nausea, sleep disturbance and the cost of monthly refills may matter greatly. Patients should feel able to describe these effects and ask why a medicine is necessary, how long it is expected to continue and which alternatives exist. A useful review discusses risks plainly and respects a person's preferences, while recognizing that choices may require compromise between competing health goals. Making reviews routine Medication reconciliation is especially useful after hospital discharge, following a new diagnosis or when a regimen becomes hard to manage. Ongoing reviews can prevent small discrepancies from accumulating over time. The outcome should be a current list, a rationale for each important change, any monitoring arrangements and a clear contact for questions. Safer prescribing is not simply about adding the latest treatment; sometimes the most thoughtful intervention is to review what is already there. What a useful medication plan looks like At the end of a review, the patient should ideally have a clearly dated medication list and understand the intended purpose of each treatment. Changes should identify what to start, continue, adjust or stop, with written instructions when tapering is necessary. The team may also explain which symptoms warrant urgent attention and which routine checks are needed to judge whether a change is working. Where multiple professionals are involved, the updated plan should be shared with those responsible for ongoing prescriptions. That creates a practical bridge between an informed discussion and safer daily medicine use.
GLP-1 Medicines Beyond Weight Loss: What Heart and Kidney Benefits Really Mean
Naloxone works best when people have an emergency plan
